Evaxion Biotech AS (EVAX) Stock Price

Evaxion Biotech AS Price

NYSE·CLOSED
3.66
​
Market closed

Over the last 2 years Evaxion Biotech AS grew revenue by 915.5% annually, reaching 7.53 M USD. For Evaxion Biotech AS, the net margin of -102.4% is up versus -30,308.2% a few years ago. The consensus 12-month price target for Evaxion Biotech AS is 9.00 USD, about 145.9% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.

Evaxion Biotech AS stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evaxion Biotech AS business model & stock analysis

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Frequently asked questions about Evaxion Biotech AS

Analysts currently set an average price target of 9.00 USD for the Evaxion Biotech AS stock (median: 9.00 USD), implying +145.9 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the Evaxion Biotech AS stock: 9 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Evaxion Biotech AS share trades at 3.27 EUR (3.66 USD).

The revenue cannot currently be calculated for Evaxion Biotech AS.

The expected profit of Evaxion Biotech AS is -333,608.57 USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Evaxion Biotech AS is currently -70.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Evaxion Biotech AS stock.

The P/S cannot be calculated for Evaxion Biotech AS currently.

The Eulerpool Quality Score for Evaxion Biotech AS is 3/10.

The ISIN of Evaxion Biotech AS is US29970R3030. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Evaxion Biotech AS is EVAX. The ticker symbol is used to trade Evaxion Biotech AS shares on the stock exchange.

Fair ValueTerminal
3.48 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
167,288.89 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website evaxion.ai
Currency
USD
Initial public offering
Feb 5, 2021
ISIN
US29970R3030
Cusip
29970R105
Market capitalization
30.53 M USDMicro Cap
52-Week Range
PEG
0.13
P/E ratio
P/Ee 2026
-70.30
P/Ee 2027
-187.47
P/Ee 2028
-93.74
P/Ee 2029
45.75
P/Ee 2030
-281.21
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.79
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-31.40 %
Last updated Oct 24, 2026, 12:16 PM

Evaxion Biotech AS Peer Group